[go: up one dir, main page]

WO2011112166A1 - Method of treatment - Google Patents

Method of treatment Download PDF

Info

Publication number
WO2011112166A1
WO2011112166A1 PCT/US2010/000745 US2010000745W WO2011112166A1 WO 2011112166 A1 WO2011112166 A1 WO 2011112166A1 US 2010000745 W US2010000745 W US 2010000745W WO 2011112166 A1 WO2011112166 A1 WO 2011112166A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
magnesium
weight
vaginal
chloride
Prior art date
Application number
PCT/US2010/000745
Other languages
French (fr)
Inventor
Scott Cordray
Original Assignee
Scott Cordray
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott Cordray filed Critical Scott Cordray
Priority to EP10847583A priority Critical patent/EP2544543A1/en
Priority to CA2795977A priority patent/CA2795977A1/en
Priority to PCT/US2010/000745 priority patent/WO2011112166A1/en
Publication of WO2011112166A1 publication Critical patent/WO2011112166A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • the present invention is related to the method and composition for treating a patient suffering from irritations and inflammation of a cutaneous or mucosal surface of a mammal. More particularly, there is provided a method of treatment of inflammation in the vaginal cavity while mamtaining normal vaginal floral activity and to treat cutaneous and anal/vaginal irritation and inflammation with magnesium and alkali metal salts.
  • hemorrhoids The most common anorectal irritation or inflammation is caused by hemorrhoids. This condition can be caused by poor sanitary conditions, constipation, bacterial infection, etc. Common treatment is with sanitary wipes, suppositories and gels.
  • vaginal cavity is subject to conditions which render it as a target for disease and infection; however, it is extremely difficult to deliver an active agent to this area for an extended period of time.
  • the vaginal cavity exhibits an aqueous environment containing secreting glands whose fluids create an acidic pH in the range of 3.5 to 5.5.
  • the environment of the vagina is conducive to the growth of bacteria, fungi, yeast and other microorganisms since it is warm, moist, and dark. It is also the vestibule for menstrual debris and residual seminal fluid from sexual intercourse.
  • the crevices of the vaginal cavity facilitate the retention of undesirable bacteria, fungi, yeast, and other microorganisms as well as the debris from menstruation and sexual intercourse.
  • the vaginal cavity is also subject to considerable physical deformation, such as during sexual intercourse or the insertion of tampons.
  • vulvovaginitis Infectious diseases and other inflammatory conditions affecting the vaginal mucosa and often secondarily involving the vulva are commonly referred to as vulvovaginitis. Physicians and investigators often believe that the normal vaginal flora has a nice role in protecting the vagina and contiguous tissues from various microorganisms that are causes of vulvovaginitis.
  • vulvovaginitis and symptomatic vaginal discharges are caused by bacteria, usually Gardnerella vaginalis in combination with various anaerobes.
  • Protozoa Trichomonas vaginalis
  • Candida is a frequent cause in pregnant women and diabetics, and occasionally oral contraceptives increase susceptibility.
  • Candida also causes symptoms in women who do not have the risk factors of diabetes, pregnancy, and hormonal therapy.
  • Other less common causes of vulvovaginitis are other bacteria (e.g.
  • Neisseria gonorrhoeae members of the Chlamydia and Mycoplsma groups, streptococci, Escherichiacoli, and staphylococci), foreign bodies, viral infections (herpes simplex and HIV infections), pinworms (Enterobius vermicularis), rituals, radiation, and tumors of the genital tract. Frequent douching, especially with chemicals, may disturb normal vaginal milieu. Deodorant sprays, laundry soaps and fabric softeners, and bath water additives may cause vulvar irritation and inflammation. Tight, nonporous, nonabsorbent underclothing, as well as poor hygiene, may foster fungal and bacterial growth. Occasionally, sensitivity to spermicides, coital lubricants, or latex in a diaphragm or condom causes irritation and inflammation.
  • the pH of a healthy vaginal is mildly acidic (pH 3.5-4.5) and this acidity is thought to be generated by the production of lactic acid by lactobacilli, which form a major component of the healthy vaginal flora. Together with other factors, this acid pH is widely recognized to prevent overgrowth of undesirable endogenous microbes (Candida, harmful anaerobes, and bacteria that may cause urinary tract infections) and encourages the continued dominance of lactobacilli which, in addition to mild acidity, provides other protective mechanisms such as production of hydrogen peroxide which aids in modulating cell growth of other microbial species.
  • sperms are inactivated by the mild acidity of the healthy vagina, and acid substances have been used as home made vaginal contraceptives for centuries. More recently, it has been recognized that many sexually transmitted disease pathogens and most or all enveloped STD (sexually transmitted disease) viruses (Kempf 1001, Martin 1985) including herpes simplex virus, cytomegalovirus, and human immunodeficiency virus, are also inhibited or inactivated by mild acidic pH.
  • STD sexually transmitted disease
  • semen contains a potent alkaline buffering capacity that neutralizes the vaginal acidity for a period of many hours after intercourse. The alkaline buffering capacity enables sperm to swim from the vagina into the cervix and upper reproductive tract.
  • the elevated pH also allows certain strains of Staphylococcus aureus to produce shock toxin I, whereas production of this toxin is completely inhibited at acidic pH 5.0 (Schlievert 1983).
  • loss of protective acidity may result in staphylococcal toxic shock syndrome, Candida vaginitis, bacterial vaginosis, or urinary tract infection.
  • the present invention relates to method for treating a patient suffering from cutaneous or mucosal surface irritations and inflammations with the proviso that oral mucosal surfaces are excluded. More particularly, there is provided a method comprising administering an effective amount of a composition composed of: a) about 0.5 to 20% by weight, preferably about 0.6 to 10% by weight of salts comprising
  • magnesium salts selected from the group consisting of magnesium bromide, magnesium chloride, magnesium citrate and magnesium sulfate, preferably about 55 to 88% by weight of magnesium bromide is used,
  • the composition can be buffered to a pH between about 3.5 to 6.5, preferably between 3.5 and 5.5 when used vaginally or 5-8 when use is cutaneously.
  • composition can be in the form of a douche, gel, suppository, cream or foam.
  • the present invention relates to a method for treatment of a patient suffering from cutaneous and mucosal surfaces for inflammation and irritations, excluding oral cavities. More particularly, there is provided a composition for use in the method which comprises:
  • salts selected from the group consisting of magnesium bromide, magnesium chloride and magnesium sulfate, preferably with magnesium bromide being the majority;
  • composition is buffered to a pH between about 3.5 to 5.5 when used vaginally or for treating the urinary bladder. .
  • chloride salts aids in cell membrane lysis. Also, chloride ions augment the antimicrobial activity of endogenous that contribute to protection against bacterial pathogens.
  • Magnesium salts have been found to inhibit the activation of arachadonic acid and 5-lipoxygenase enzyme which are associated with pain.
  • Magnesium bromide inhibits the activation of white blood cells and particularly activate kinase activity.
  • White blood cells are pro-inflammatory so that their inhibition reduces further irritation.
  • Non-limiting examples of wounds of a mucosal surface or cutaneous surface of a mammal include burns, surgical wounds, wounds of bleeding hemorrhoids, vaginitis, radiation burns and non-surgical traumatic wounds.
  • the mucosal surface includes urethral mucosa, especially radiation urethritis, and urinary bladder mucosa can be treated.
  • the acidic or non-acidic composition may be presented in liquid and forms normally used for topical application, in particular in the form of aqueous, aqueous-alcoholic or, oil solutions, or lipophilic gels, or emulsions of liquid or semi-solid consistency of the milk type, obtained by dispersing a fatty phase in an aqueous phase (O W) or vice versa (W/O), or of suspensions or emulsions of soft, semi-solid consistency of the gel types.
  • These compositions are prepared according to standard methods.
  • ком ⁇ онентs are preferably used in the form of aqueous solutions, or in the form of gels, foams, or suppositories.
  • compositions according to the invention are those traditionally used in the pharmaceutical field.
  • the composition of the invention may also contain adjuvants which are customary in the pharmaceutical field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes and fillers.
  • adjuvants which are customary in the pharmaceutical field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes and fillers.
  • the amounts of these different adjuvants are those traditionally used in the pharmaceutical or dermatological field, and are, for example from 0.01% to 10% of the total weight of the composition. Those adjuvants, depending on their nature may be introduced into the fatty phase or into the aqueous phase.
  • carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, clays and natural gums may be mentioned.
  • Natural gums which may be used includes carageenan gum, xantham gum, alginates and gelation.
  • hydrophilic active agents proteins or protein hydrolysates, amino acids, polyols, urea, allantonin, sugars and sugar derivatives, water-soluble vitamins, starch and plant extracts, in particular those of the Aloe vera may be used.
  • retinol and its derivatives
  • tocopherol vitamin E
  • essential fatty acids ceramides
  • essential oils may be used. These agents add extra moisturizing or skin softening features when utilized.
  • compositions of the invention may include plant or herbal extracts that reduce irritation.
  • extracts of Paraguay tea, Kola and Guarana which provide a source of methylxanthines, saponius, tannins, and glycosides that have been shown to be anti-inflammatory and can be used to treat irritations.
  • the extract of Paraguay tea is known as "Mate extract” and is described in the "International Cosmetic Ingredient Dictionary", 5 th Edition.
  • Mate extract is commercially available in combination with extracts of Koa and Guarana, which is sold by Cosmetic Ingredient Resources of Stamford, CT under the trademark "QUENCHT”.
  • a surfactant can be included in the composition so as to provide deeper penetration of the ingredients.
  • Many surfactants are also antimicrobial agents, for example, nonoxynol-9 and octoxynol-p are used to prevent HTV.
  • HISPAGEL a glycol-free glycerine clarthrate which is generally described as glycerin polyacrylate which is sold by Centerchem Inc. of Stamford, Ct. Generally, up to about 20% by weight of the composition comprises HISPAGEL. It can be used in combination with other gellants such as Cabopols, cellulose derivatives, clays and the like.
  • the preferred natural gums that can be used in amounts up to about 5% by weight include carageenan gum, xantham gum, alginates, and gelatin.
  • the preferred synthetic polymers that can be used include Carbopol, polyacrylic acid, polymethacrylic acid, hydroxyalkyl cellulose, methacrylate, and polyacrylamide.
  • compositions may contain an additional therapeutic active agent as well as a spermicide.
  • the additional active agent may be any of those which are approved for or used for the treatment, propylaxis, cure or mitigation of any disease of the vulva, vagina, urinary tract, cervix or other female reproductive organ or preventant of conception; for aesthetic or cosmetic usage, for diagnostic purposes; for systemic drug therapy.
  • the agent must have utility when administered by delivery to all or a portion of the vaginal surfaces.
  • Therapeutic active agents are normally well-known. Without being limited thereto, exemplary agents include:
  • Antibacterial agents such as C31G, trimethoprim, sulfamethoxazole, and Chloromycetin;
  • antiseptic agents such as chlorhexidine gluconate
  • antibiotic agents such as erythromycin, penicillins, cephalosporins and their derivatives, ampicillin, methicillin, and doxycycline;
  • antiparasitic agents such as thiabendazole
  • antiprotozoal agents such as metronidazole, and chloroquine hydrochloride
  • antiviral agents such as dextran sulfate and other sulfated polysaccharides, n- Docosanol (Lidak Pharmaceuticals), squalamine, and vidarabine;
  • antifungal agents such as ketoconazole, flucytosine, itraconazole, amphotericin B, nystatin, butoconazole nitrate, and clotrimazole.
  • the preparations of this invention must possess a pH between 3.5 to about 5.5 and preferably between about 4 and 5.5 for vaginal use. pH's above 6.5 are not preferred since they promote vaginal infections and inflammation.
  • buffers are used to adjust the pH of the system. Acceptable buffers include commonly used mixtures of a weak acid and its conjugate base, such as acetic acid and sodium acetate. Acceptable buffers may be based on inorganic salts such as phosphate and carbonate, and organic acid sodium and potassium salts such as acetate, citrate, succinate, formate, glycine, maleate, phosphates and barbiturates, with sodium citrate being preferred.
  • the microbial kill rate for undesirable microbes is 20 to 50 times more effective at pH's about 4.0 for vaginal use.
  • a pH of 5-8 can be used for cutaneous irritations.
  • the gelled compositions of this invention are formed by preparing a translucent gel of the polymer in a suitable carrier.
  • One procedure would involve mixing the acrylic acid polymer with glycerine until the polymer is completely absorbed by the glycerine.
  • Acceptable amounts of polymer to glycerine for this purpose may range from a ratio of 1 :5 to 20 w/w. It should be recognized that other processes may be used to prepare the composition of this invention depending on the vehicle being used to prepare the gel composition and excipients employed.
  • compositions may contain an additional therapeutic active agent as well as a spermicide.
  • the additional active agent may be any of those which are approved for or used for the treatment, prophylaxis, cure or mitigation of any disease of the vulva, vagina, urinary tract, cervix or other female reproductive organ.
  • a preferred 100 ml composition of the present invention comprises:
  • the pharmaceutical compositions may be prepared for a vaginal douche or a urinary bladder wash according to standard formulating procedures.
  • the salts may be dissolved in sterile water, and buffered to a pH of 3.5 to 5.5 which is advantageously ionically balanced.
  • a preferred buffering agent is sodium hydrogen phosphate.
  • a preservative for example, TTiimerosal or benzalkonium chloride and/or an antioxidant, for example, vitamin E.
  • an antioxidant for example, vitamin E.
  • Other filler materials which can be included are commonly found in douche or enema compositions.
  • Osmotic pressure is a main cause for the movement of water across cell membranes and is defined as the hydrostatic pressure needed to stop the net flow of water across a membrane, e.g., a cell membrane.
  • the osmotic process occurs because there is a physical and chemical tendency for solutions on different sides of a semi-permeable membrane to try to have the same concentrations of solutes in them.
  • the osmolality of the compositions of the present invention can be regulated by changing the amounts of any of all components.
  • the most practical method of regulating the osmolality is to change the amount of single or multiple chemical components (normally present in a large enough amount to allow varying the osmolality over a sufficient range) whose alterations will not significantly affect either the stability, the efficacy, or the other physical-chemical properties (pH, viscosity) of the composition. Based on these criteria, it is preferred to regulate the osmolality by varying the amount of the source of anions and/or source of cations. It is present in adequate amounts to allow varying the osmotic pressure over a sufficient range for various compositions. Varying amounts of, for example, magnesium chloride over the necessary range does not significantly affect the stability, the efficacy, the pH, or the viscosity of the composition. Any of the other chemical components can be varied to adjust the osmolality.
  • a theoretical calculation may be performed to predict the osmolality based on the amounts of the chemical components in the composition. This is useful for an initial estimate, however, using an osmometer to measure osmolality is the method of choice.
  • Osmometers are standard, reliable, and relatively easy to operate instruments, which give actual measurements that allow determination of the osmolality of the formulation of compositions with high precision.
  • a 100 ml solution which is effective as a vaginal douche or urinary bladder wash is prepared as follows:
  • composition is buffered to pH 4.0.
  • the composition contains about 0.5% of nonoxynol-9.
  • composition may be used to treat vaginal or cutaneous irritations.
  • Example 3 The composition may be used to treat vaginal or cutaneous irritations.
  • a lubricant is prepared by admixing the following ingredients.
  • the composition can be used to treat hemorrhoids or cutaneous irritations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Method and compositions for treating cutaneous and mucosal irritations and inflammations with a composition containing magnesium and alkali metal salts. The irritations include bleeding resulting from radiation or surgery.

Description

METHOD OF TREATMENT
Field of the Invention
The present invention is related to the method and composition for treating a patient suffering from irritations and inflammation of a cutaneous or mucosal surface of a mammal. More particularly, there is provided a method of treatment of inflammation in the vaginal cavity while mamtaining normal vaginal floral activity and to treat cutaneous and anal/vaginal irritation and inflammation with magnesium and alkali metal salts.
Background of the Invention
The most common anorectal irritation or inflammation is caused by hemorrhoids. This condition can be caused by poor sanitary conditions, constipation, bacterial infection, etc. Common treatment is with sanitary wipes, suppositories and gels.
Other anal inflammations are involved with anal fissures, anorectal fistula and proctitis.
One of the main disciplines of medicine is the treatment of the female reproductive system for the prevention, treatment, mitigation, diagnosis, and cure of diseases, and the prevention of conception. Usually, this involves the delivery of active agents to the vaginal cavity and its environs. Systems to affect the delivery of such agents are usually in the form of gels, foams, creams, or suppositories and quick dissolving tablets. The vaginal cavity is subject to conditions which render it as a target for disease and infection; however, it is extremely difficult to deliver an active agent to this area for an extended period of time. The vaginal cavity exhibits an aqueous environment containing secreting glands whose fluids create an acidic pH in the range of 3.5 to 5.5. The environment of the vagina is conducive to the growth of bacteria, fungi, yeast and other microorganisms since it is warm, moist, and dark. It is also the vestibule for menstrual debris and residual seminal fluid from sexual intercourse. The crevices of the vaginal cavity facilitate the retention of undesirable bacteria, fungi, yeast, and other microorganisms as well as the debris from menstruation and sexual intercourse. The vaginal cavity is also subject to considerable physical deformation, such as during sexual intercourse or the insertion of tampons.
Infectious diseases and other inflammatory conditions affecting the vaginal mucosa and often secondarily involving the vulva are commonly referred to as vulvovaginitis. Physicians and investigators often believe that the normal vaginal flora has a nice role in protecting the vagina and contiguous tissues from various microorganisms that are causes of vulvovaginitis.
Most vulvovaginitis and symptomatic vaginal discharges are caused by bacteria, usually Gardnerella vaginalis in combination with various anaerobes. Protozoa (Trichomonas vaginalis) cause one third of all cases. Candida is a frequent cause in pregnant women and diabetics, and occasionally oral contraceptives increase susceptibility. Candida also causes symptoms in women who do not have the risk factors of diabetes, pregnancy, and hormonal therapy. Other less common causes of vulvovaginitis are other bacteria (e.g. Neisseria gonorrhoeae, members of the Chlamydia and Mycoplsma groups, streptococci, Escherichiacoli, and staphylococci), foreign bodies, viral infections (herpes simplex and HIV infections), pinworms (Enterobius vermicularis), rituals, radiation, and tumors of the genital tract. Frequent douching, especially with chemicals, may disturb normal vaginal milieu. Deodorant sprays, laundry soaps and fabric softeners, and bath water additives may cause vulvar irritation and inflammation. Tight, nonporous, nonabsorbent underclothing, as well as poor hygiene, may foster fungal and bacterial growth. Occasionally, sensitivity to spermicides, coital lubricants, or latex in a diaphragm or condom causes irritation and inflammation.
The pH of a healthy vaginal is mildly acidic (pH 3.5-4.5) and this acidity is thought to be generated by the production of lactic acid by lactobacilli, which form a major component of the healthy vaginal flora. Together with other factors, this acid pH is widely recognized to prevent overgrowth of undesirable endogenous microbes (Candida, harmful anaerobes, and bacteria that may cause urinary tract infections) and encourages the continued dominance of lactobacilli which, in addition to mild acidity, provides other protective mechanisms such as production of hydrogen peroxide which aids in modulating cell growth of other microbial species.
It is also known that sperms are inactivated by the mild acidity of the healthy vagina, and acid substances have been used as home made vaginal contraceptives for centuries. More recently, it has been recognized that many sexually transmitted disease pathogens and most or all enveloped STD (sexually transmitted disease) viruses (Kempf 1001, Martin 1985) including herpes simplex virus, cytomegalovirus, and human immunodeficiency virus, are also inhibited or inactivated by mild acidic pH. However, semen contains a potent alkaline buffering capacity that neutralizes the vaginal acidity for a period of many hours after intercourse. The alkaline buffering capacity enables sperm to swim from the vagina into the cervix and upper reproductive tract.
Unfortunately, STD pathogens in genital secretions can also exploit this period of neutral vaginal pH, since it allows time for them to reach and infect their target cells. If this semen-induced neutralization of vaginal acidity could be promptly and reliably overcome, both contraception and STD prevention could be achieved by a method that closely mimics the normal physiological state of the vagina.
In addition, the elevated pH also allows certain strains of Staphylococcus aureus to produce shock toxin I, whereas production of this toxin is completely inhibited at acidic pH 5.0 (Schlievert 1983). Thus, loss of protective acidity may result in staphylococcal toxic shock syndrome, Candida vaginitis, bacterial vaginosis, or urinary tract infection.
Summary of the Invention
The present invention relates to method for treating a patient suffering from cutaneous or mucosal surface irritations and inflammations with the proviso that oral mucosal surfaces are excluded. More particularly, there is provided a method comprising administering an effective amount of a composition composed of: a) about 0.5 to 20% by weight, preferably about 0.6 to 10% by weight of salts comprising
1) about 45 to 60% by weight of magnesium salts selected from the group consisting of magnesium bromide, magnesium chloride, magnesium citrate and magnesium sulfate, preferably about 55 to 88% by weight of magnesium bromide is used,
2) about 29 to 41% by weight of potassium chloride, preferably about 39 to 40% by weight,
3) about 0 to 2% by weight of calcium salts, and
4) a buffer,
b) the remainder being a suitable pharmaceutically acceptable vehicle.
The composition can be buffered to a pH between about 3.5 to 6.5, preferably between 3.5 and 5.5 when used vaginally or 5-8 when use is cutaneously.
The composition can be in the form of a douche, gel, suppository, cream or foam.
It is therefore a general object of the invention to treat anal and/or vaginal and other mucosal irritations and inflammations while maintaining a proper pH.
It is another object of the invention to treat cutaneous irritations.
It is still another object of the invention to provide a vaginal douche or urinary bladder wash to maintain an acid environment in the vaginal cavity. Description of the Preferred Embodiments
The present invention relates to a method for treatment of a patient suffering from cutaneous and mucosal surfaces for inflammation and irritations, excluding oral cavities. More particularly, there is provided a composition for use in the method which comprises:
a) about 0.5 to 20% by weight, preferably about 0.6 to 10% by weight of salts comprising
1) about 45 to 60% by weight of salts selected from the group consisting of magnesium bromide, magnesium chloride and magnesium sulfate, preferably with magnesium bromide being the majority;
2) about 29 to 41% by weight of potassium chloride, preferably about 39 to 41% by weight,
3) about 0 to 2% by weight of calcium salts, and
4) a buffer,
b) the remainder being a suitable pharmaceutically acceptable vehicle.
The composition is buffered to a pH between about 3.5 to 5.5 when used vaginally or for treating the urinary bladder. .
The presence of chloride salts aids in cell membrane lysis. Also, chloride ions augment the antimicrobial activity of endogenous that contribute to protection against bacterial pathogens.
Magnesium salts have been found to inhibit the activation of arachadonic acid and 5-lipoxygenase enzyme which are associated with pain. Magnesium bromide inhibits the activation of white blood cells and particularly activate kinase activity. White blood cells are pro-inflammatory so that their inhibition reduces further irritation.
By inhibiting white blood cell activation there is also inhibiting neutrophils, lymphocites, eosinophils and basophils which are related to pro-inflammatory activity.
Non-limiting examples of wounds of a mucosal surface or cutaneous surface of a mammal include burns, surgical wounds, wounds of bleeding hemorrhoids, vaginitis, radiation burns and non-surgical traumatic wounds. The mucosal surface includes urethral mucosa, especially radiation urethritis, and urinary bladder mucosa can be treated.
The acidic or non-acidic composition, according to the invention, may be presented in liquid and forms normally used for topical application, in particular in the form of aqueous, aqueous-alcoholic or, oil solutions, or lipophilic gels, or emulsions of liquid or semi-solid consistency of the milk type, obtained by dispersing a fatty phase in an aqueous phase (O W) or vice versa (W/O), or of suspensions or emulsions of soft, semi-solid consistency of the gel types. These compositions are prepared according to standard methods.
They are preferably used in the form of aqueous solutions, or in the form of gels, foams, or suppositories.
The amounts of the different constituents of the compositions according to the invention are those traditionally used in the pharmaceutical field. In a known manner, the composition of the invention may also contain adjuvants which are customary in the pharmaceutical field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes and fillers. The amounts of these different adjuvants are those traditionally used in the pharmaceutical or dermatological field, and are, for example from 0.01% to 10% of the total weight of the composition. Those adjuvants, depending on their nature may be introduced into the fatty phase or into the aqueous phase.
As hydrophilic gelling agents, carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, clays and natural gums may be mentioned.
Natural gums which may be used includes carageenan gum, xantham gum, alginates and gelation. As hydrophilic active agents, proteins or protein hydrolysates, amino acids, polyols, urea, allantonin, sugars and sugar derivatives, water-soluble vitamins, starch and plant extracts, in particular those of the Aloe vera may be used.
As lipophilic active agents, retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides and essential oils may be used. These agents add extra moisturizing or skin softening features when utilized.
The compositions of the invention may include plant or herbal extracts that reduce irritation. For example, there may be utilized extracts of Paraguay tea, Kola and Guarana, which provide a source of methylxanthines, saponius, tannins, and glycosides that have been shown to be anti-inflammatory and can be used to treat irritations. The extract of Paraguay tea is known as "Mate extract" and is described in the "International Cosmetic Ingredient Dictionary", 5th Edition. Mate extract is commercially available in combination with extracts of Koa and Guarana, which is sold by Cosmetic Ingredient Resources of Stamford, CT under the trademark "QUENCHT".
A surfactant can be included in the composition so as to provide deeper penetration of the ingredients. Many surfactants are also antimicrobial agents, for example, nonoxynol-9 and octoxynol-p are used to prevent HTV. Generally, about 0.05 to 2.0% by weight surfactant can be used.
An example of a lubricating base which can be used is HISPAGEL a glycol-free glycerine clarthrate which is generally described as glycerin polyacrylate which is sold by Centerchem Inc. of Stamford, Ct. Generally, up to about 20% by weight of the composition comprises HISPAGEL. It can be used in combination with other gellants such as Cabopols, cellulose derivatives, clays and the like.
The preferred natural gums that can be used in amounts up to about 5% by weight include carageenan gum, xantham gum, alginates, and gelatin.
The preferred synthetic polymers that can be used include Carbopol, polyacrylic acid, polymethacrylic acid, hydroxyalkyl cellulose, methacrylate, and polyacrylamide.
The compositions may contain an additional therapeutic active agent as well as a spermicide. The additional active agent may be any of those which are approved for or used for the treatment, propylaxis, cure or mitigation of any disease of the vulva, vagina, urinary tract, cervix or other female reproductive organ or preventant of conception; for aesthetic or cosmetic usage, for diagnostic purposes; for systemic drug therapy. The agent must have utility when administered by delivery to all or a portion of the vaginal surfaces. Therapeutic active agents are normally well-known. Without being limited thereto, exemplary agents include:
Antibacterial agents such as C31G, trimethoprim, sulfamethoxazole, and Chloromycetin;
antiseptic agents such as chlorhexidine gluconate;
antibiotic agents such as erythromycin, penicillins, cephalosporins and their derivatives, ampicillin, methicillin, and doxycycline;
antiparasitic agents such as thiabendazole;
antiprotozoal agents such as metronidazole, and chloroquine hydrochloride;
antiviral agents such as dextran sulfate and other sulfated polysaccharides, n- Docosanol (Lidak Pharmaceuticals), squalamine, and vidarabine;
and antifungal agents such as ketoconazole, flucytosine, itraconazole, amphotericin B, nystatin, butoconazole nitrate, and clotrimazole.
The preparations of this invention must possess a pH between 3.5 to about 5.5 and preferably between about 4 and 5.5 for vaginal use. pH's above 6.5 are not preferred since they promote vaginal infections and inflammation. When necessary, buffers are used to adjust the pH of the system. Acceptable buffers include commonly used mixtures of a weak acid and its conjugate base, such as acetic acid and sodium acetate. Acceptable buffers may be based on inorganic salts such as phosphate and carbonate, and organic acid sodium and potassium salts such as acetate, citrate, succinate, formate, glycine, maleate, phosphates and barbiturates, with sodium citrate being preferred.
It has also been unexpectedly found that the microbial kill rate for undesirable microbes is 20 to 50 times more effective at pH's about 4.0 for vaginal use. A pH of 5-8 can be used for cutaneous irritations.
The gelled compositions of this invention are formed by preparing a translucent gel of the polymer in a suitable carrier. One procedure would involve mixing the acrylic acid polymer with glycerine until the polymer is completely absorbed by the glycerine. Acceptable amounts of polymer to glycerine for this purpose may range from a ratio of 1 :5 to 20 w/w. It should be recognized that other processes may be used to prepare the composition of this invention depending on the vehicle being used to prepare the gel composition and excipients employed.
As discussed above, the compositions may contain an additional therapeutic active agent as well as a spermicide. The additional active agent may be any of those which are approved for or used for the treatment, prophylaxis, cure or mitigation of any disease of the vulva, vagina, urinary tract, cervix or other female reproductive organ.
A preferred 100 ml composition of the present invention comprises:
Ingredient Wt.
Magnesium Bromide 1.0 2.00 g Magnesium Chloride 0.01 0.05 g Magnesium Sulfate 0.01 0.05 g Potassium Chloride 0.08 1.00 g Calcium Chloride 0 0.05 g Sodium Carbonate 0 0.05 g Water q.s. The pharmaceutical compositions may be prepared for a vaginal douche or a urinary bladder wash according to standard formulating procedures.
The salts may be dissolved in sterile water, and buffered to a pH of 3.5 to 5.5 which is advantageously ionically balanced. A preferred buffering agent is sodium hydrogen phosphate.
It is preferred to include a preservative, for example, TTiimerosal or benzalkonium chloride and/or an antioxidant, for example, vitamin E. Other filler materials which can be included are commonly found in douche or enema compositions.
Osmolality
Osmotic pressure is a main cause for the movement of water across cell membranes and is defined as the hydrostatic pressure needed to stop the net flow of water across a membrane, e.g., a cell membrane. The osmotic process occurs because there is a physical and chemical tendency for solutions on different sides of a semi-permeable membrane to try to have the same concentrations of solutes in them.
In the most general sense, the osmolality of the compositions of the present invention can be regulated by changing the amounts of any of all components.
In a specific sense, the most practical method of regulating the osmolality is to change the amount of single or multiple chemical components (normally present in a large enough amount to allow varying the osmolality over a sufficient range) whose alterations will not significantly affect either the stability, the efficacy, or the other physical-chemical properties (pH, viscosity) of the composition. Based on these criteria, it is preferred to regulate the osmolality by varying the amount of the source of anions and/or source of cations. It is present in adequate amounts to allow varying the osmotic pressure over a sufficient range for various compositions. Varying amounts of, for example, magnesium chloride over the necessary range does not significantly affect the stability, the efficacy, the pH, or the viscosity of the composition. Any of the other chemical components can be varied to adjust the osmolality.
In performing an adjustment of the osmolality, a theoretical calculation may be performed to predict the osmolality based on the amounts of the chemical components in the composition. This is useful for an initial estimate, however, using an osmometer to measure osmolality is the method of choice. Osmometers are standard, reliable, and relatively easy to operate instruments, which give actual measurements that allow determination of the osmolality of the formulation of compositions with high precision.
The following examples illustrate the invention.
Example 1
A 100 ml solution which is effective as a vaginal douche or urinary bladder wash is prepared as follows:
Ingredient
Magnesium Bromide
Magnesium Chloride
Magnesium Sulfate
Potassium Chloride
Potassium sorbate solution
Calcium Chloride
Purified Water
The composition is buffered to pH 4.0.
Optionally, the composition contains about 0.5% of nonoxynol-9.
Example 2
Preparation of a gel.
Ingredients % W7W
Magnesium bromide 1.60
Phytosphingosine 0.05
Magnesium Chloride 0.05
Magnesium sulfate 0.03
Carbopol 940 0.4
Potassium Chloride 1.0
Butylene glycol 6.5
Quench T 3.0
Chamomile glycolic extract 3.0
Sodium hydrogenphosphate 0.5
Preservative 0.1
Fragrance 0.1
Deionized Water
100%
To 20 ml of water with stirring, is added the Carbopol 940. The mixture is stirred until hydration is complete and then butylenes glycol is added. The remaining ingredients are mixed together and added to the first mixture. The mixing is continued until uniform. Optionally, 0.2% clotrimazole is added.
The composition may be used to treat vaginal or cutaneous irritations. Example 3
A lubricant is prepared by admixing the following ingredients.
Ingredients % WAV
Hispagel 20.0
Magnesium bromide 1.2
Magnesium Chloride 0.05
Flax Oil 1.0
Carbopol 940 0.4
Butylene Glycol 6.0
Potassium hydrogen phosphate 0.1
Citric Acid 0.5
Saffron 0.2
Potassium Chloride 0.8
Deionized Water q.s.
100% of the composition is adjusted to 4.0.
The composition can be used to treat hemorrhoids or cutaneous irritations.

Claims

What is Claimed
1. A method for the treatment of a patient for cutaneous and mucosal surfaces irritation and inflammation which comprises administering an effective amount of a composition composed of;
a) about 0.5 to 20% by weight of salts comprising;
1) about 45 to 60% by weight of magnesium salts selected from the group consisting of magnesium bromide, magnesium chloride, magnesium citrate, and magnesium sulfate;
2) about 29 to 41% by weight of a potassium salt;
3) about 0 to 2% by weight of a calcium salt;
4) a suitable buffer
b) the remainder being a suitable pharmaceutically acceptable carrier, with the proviso that oral mucosa is omitted from treatment.
2. The method of claim 1 in which said composition has a pH between 3.5 and 5.5.
3. The method of claim 1 wherein the patient is suffering from vaginal yeast infection.
4. The method of claim 1 wherein said composition is a vaginal douche or a urinary bladder wash.
5. The method of claim 1 wherein said composition is a foam or gel.
6. The method of claim 1 wherein 100 ml of said composition consists of:
Ingredient Wt.
Magnesium Bromide 1.0 - 2.00 g
Magnesium Chloride 0.01 - 0.05 g
Magnesium Sulfate 0.01 - 0.05 g
Potassium Chloride 0.08 - 1.00 g
Calcium Chloride 0.0 - 0.05 g
Sodium Carbonate 0 - 0.05 g
Water q.s.
Said composition having a pH between 3.5 to 5.5 for vaginal use and 5 to 8 for cutaneous applications.
7. The method of claim 1 wherein surgical bleeding is treated.
8. The method of claim 1 wherein anti-bacterial agents are included in said composition.
9. The method of claim 1 wherein said composition contains anti-fungal agents.
10. The method of claim 1 wherein said composition is in the form selected from the Group consisting of foam, gel or liquid.
11. The method of claim 1 wherein bleeding is controlled.
PCT/US2010/000745 2010-03-12 2010-03-12 Method of treatment WO2011112166A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10847583A EP2544543A1 (en) 2010-03-12 2010-03-12 Method of treatment
CA2795977A CA2795977A1 (en) 2010-03-12 2010-03-12 Method of treatment
PCT/US2010/000745 WO2011112166A1 (en) 2010-03-12 2010-03-12 Method of treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/000745 WO2011112166A1 (en) 2010-03-12 2010-03-12 Method of treatment

Publications (1)

Publication Number Publication Date
WO2011112166A1 true WO2011112166A1 (en) 2011-09-15

Family

ID=44563741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000745 WO2011112166A1 (en) 2010-03-12 2010-03-12 Method of treatment

Country Status (3)

Country Link
EP (1) EP2544543A1 (en)
CA (1) CA2795977A1 (en)
WO (1) WO2011112166A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884049B2 (en) 2014-07-14 2018-02-06 Orion Biotechnology Canada Ltd. Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151543A1 (en) 2013-03-15 2015-11-29 Braintree Lab ORAL PHARMACEUTICAL COMPOSITION OF SULPHATE SALTS FOR DUAL USE TABLETS AND METHODS FOR ITS USE
CN103405591A (en) * 2013-05-30 2013-11-27 闫一粼 Nourishing type water-soluble personal lubricant and preparation method thereof, and condom

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
US5968500A (en) * 1989-10-31 1999-10-19 Columbia Laboratories, Inc. Tissue moisturizing composition and method
US6150400A (en) * 1997-06-30 2000-11-21 Presutti Laboratories Method for treating vulvar vestibulitis
US20040142974A1 (en) * 2000-12-06 2004-07-22 Hoemann Michael Z. 4,4-disubstituted piperidines, and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968500A (en) * 1989-10-31 1999-10-19 Columbia Laboratories, Inc. Tissue moisturizing composition and method
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
US6150400A (en) * 1997-06-30 2000-11-21 Presutti Laboratories Method for treating vulvar vestibulitis
US20040142974A1 (en) * 2000-12-06 2004-07-22 Hoemann Michael Z. 4,4-disubstituted piperidines, and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884049B2 (en) 2014-07-14 2018-02-06 Orion Biotechnology Canada Ltd. Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof

Also Published As

Publication number Publication date
CA2795977A1 (en) 2011-09-15
EP2544543A1 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
US5741525A (en) Vaginal pharmaceutical hydrogen peroxide composition
EP1263411B1 (en) Compositions and use thereof for trapping and inactivating pathogenic microbes and spermatozoa
US5545401A (en) Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine
US6328991B1 (en) Composition and method for prevention of sexually transmitted diseases, including aids
US5527534A (en) Vaginal sponge delivery system
US20030211173A1 (en) Lubrication composition
AU2001243431A1 (en) Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
WO2006114061A1 (en) A composition and method of regulating and maintaining the vaginal bacterial flora and the normal acidity in the vaginal
JPH07509449A (en) Methods and compositions for promoting leukocyte function on mucosal or skin surfaces
US5888523A (en) Topical non-steroidal anti-inflammatory drug composition
CN107456509B (en) A kind of external application biological agent and preparation method for vagina prevention, health care and treatment gynaecology genital inflammation
ES2963980T3 (en) Emulsions for the topical treatment of dermal and mucosal infections
CN106109451A (en) A kind of antibiotic preparation and preparation method thereof
KR20050025166A (en) Warming and nonirritating lubricant antifungal gel compositions
KR20210119188A (en) Feminine vulva cleanser and method for producing the same
US20020151521A1 (en) Universal antiviral composition
JP2007077152A (en) Compositions and methods for lowering vaginal pH
EP2544543A1 (en) Method of treatment
US7687078B1 (en) Method of treatment
ES2314406T3 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ASCORBIC ACID FOR THE TREATMENT OF FUNGICAL SUPERINFECTIONS AND FUNGICAL RECURRENCES.
US20060264857A1 (en) Absorbent articles with buffer
US20080161376A1 (en) Method of treating candida isolates
US20150272986A1 (en) Composition for alleviating conditions associated with vaginal dryness
RU2498806C2 (en) Pharmaceutical formulation for treating infectious inflammatory gynaecological disorders and method for preparing it
Johnston Over-the-counter vaginal preparations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10847583

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2795977

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010847583

Country of ref document: EP